Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The prognostic value of serum paraprotein response kinetics in transplant-eligible NDMM

Luis-Esteban Tamariz-Amador • 28 Sep 2023
IMS 2023
Multiple Myeloma

In this video, Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, discusses research exploring the prognostic value of M-component kinetics in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luis-Esteban Tamariz-Amador

1:07
Highlights from the CAR-T Meeting 2024: gaining an insight into the stages of CAR-T development
Luis-Esteban Tamariz-Amador • 20 Feb 2024
1:46
The factors associated with poor outcomes following CAR-T in patients with myeloma
Luis-Esteban Tamariz-Amador • 20 Feb 2024
2:24
The prognostic value of 18FDG-PET/CT in patients with R/R multiple myeloma treated with CAR-T
Luis-Esteban Tamariz-Amador • 20 Feb 2024
1:44
Utility of 18FDG-PET/CT for risk prediction in patients with R/R myeloma undergoing CAR-T therapy
Luis-Esteban Tamariz-Amador • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals